US 7,514,078 B2
	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
Neil H. Bander, New York, N.Y. (US); Francis J. Carr, Aberdeen (United Kingdom); and Anita Hamilton, Aberdeen (United Kingdom)
Assigned to Cornell Research Foundation, Inc., Ithaca, N.Y. (US)
Filed on May 30, 2003, as Appl. No. 10/449,379.
Application 10/449379 is a continuation in part of application No. 10/379838, filed on Mar. 03, 2003, abandoned.
Application 10/379838 is a continuation in part of application No. 10/160505, filed on May 30, 2002, granted, now 7,045,605.
Claims priority of provisional application 60/295214, filed on Jun. 01, 2001.
Claims priority of provisional application 60/323585, filed on Sep. 20, 2001.
Claims priority of provisional application 60/362810, filed on Mar. 08, 2002.
Prior Publication US 2004/0120958 A1, Jun. 24, 2004
Int. Cl. A61K 39/395 (2006.01); C12P 21/04 (2006.01); C12P 21/08 (2006.01); C12N 15/02 (2006.01); C07K 16/00 (2006.01); C07H 21/04 (2006.01)

U.S. Cl. 424—133.1  [424/141.1; 424/156.1; 424/179.1; 424/181.1; 435/69.6; 435/70.21; 435/449; 530/387.3; 530/388.1; 530/391.5; 530/391.7]

140 Claims

1. A method of treating prostate cancer in a subject, comprising administering to the subject an effective amount of an anti-prostate specific membrane antigen (PSMA) antibody, or antigen binding fragment thereof, which comprises the amino acid sequence shown as SEQ ID NO:22, the amino acid sequence shown as SEQ ID NO:50, the light chain variable region amino acid sequence of the antibody produced by the NS0 cell line having ATCC Accession Number PTA-3709, or the light chain variable region amino acid sequence of the antibody produced by the NS0 cell line having ATCC Accession Number PTA-4174, such that the prostate cancer is treated.